Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis

Research in Social and Administrative Pharmacy

Volumn 8, Issue 2, 2012, Pages 145-156

  Chitnis, Abhishek S ^a   Aparasu, Rajender R ^a   Chen, Hua ^a   Johnson, Michael L ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Heart failure; Multiple propensity scores; Retrospective study

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL;

AGED; ARTICLE; COHORT ANALYSIS; FEMALE; HEART FAILURE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; RETROSPECTIVE STUDY; STATISTICS; TREATMENT OUTCOME; UNITED STATES; VETERAN;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; COHORT STUDIES; ENALAPRIL; FEMALE; FOSINOPRIL; HEART FAILURE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; VETERANS;

EID: 84863240372     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2011.03.001     Document Type: Article

References (54)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
2. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480-486.
3. National Center for Health Statistics. Centers for Disease Control and Prevention. Compressed Mortality File: Underlying Cause of Death. Atlanta, GA: Centers for Disease Control and Prevention. Available at: Accessed 11.04.09. http://wonder.cdc.gov/mortSQL.html.
4. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999, 83:1A-38A.
5. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987, 316:1429-1435. CONSENSUS Trial Study Group.
6. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
7. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302. SOLVD Investigators.
8. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676.
9. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821-828.
10. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995, 332:80-85.
11. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992, 327:669-677.
12. Garg R., Yusuf S. Overview of randomized trials of ACEI on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450-1456.
13. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial Infarction collaborative group. Lancet 2000, 355:1575-1581.
14. Gambassi G., Lapane K., Sgadari A., et al. Effects of angiotensin converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. Arch Intern Med 2000, 160:53-60.
15. Ahmed A., Kiefe C.I., Allman R.M., Sims R.V., DeLong J.F. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002, 50:1659-1666.
16. Buch P., Rasmussen S., Abildstrom S.Z., Køber L., Carlsen J., Torp-Pedersen C., TRACE investigators The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 2005, 26:145-152.
17. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
18. Sica D.A. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?. Curr Opin Nephrol Hypertens 2001, 10:597-601.
19. Tsikouris J.P., Suarez J.A., Meyerrose G.E., et al. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?. J Clin Pharmacol 2004, 44:150-157.
20. Giles T.D., Katz R., Sullivan J.M., et al. Short-and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989, 13:1240-1247.
21. Foy S.G., Crozier I.G., Turner J.G., et al. Comparison of captopril versus enalapril on left ventricular function and survival three months after acute myocardial infarction (the PRACTICAL) study. Am J Cardiol 1994, 73:1180-1186.
22. Wienbergen H., Schiele R., Gitt A., et al. Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol 2002, 90:1045-1049.
23. Pilote L., Abrahamowicz M., Rodrigues E., Eisenberg M.J., Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?. Ann Intern Med 2004, 141:102-112.
24. Pilote L., Abrahamowicz M., Eisenberg M., Humphries K., Behlouli H., Tu J.V. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008, 178:1303-1311.
25. Gavazzi A., Marioni R. Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure. J Hypertens 1994, 12:S89-S93.
26. Bach R., Zardini P. Long-acting angiotensin-converting enzyme inhibition: once-daily lisinopril versus twice-daily captopril in mild-to-moderate heart failure. Am J Cardiol 1992, 70:70C-77C.
27. Borghi C., Ambrosinoni E. Survival of myocardial infarction long-term evaluation-2 working party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the survival of myocardial Infarction long-term evaluation-2 (SMILE-2) study. Am Heart J 2003, 145:80-87.
28. Tu K., Mamdani M., Kopp A., Lee D. Comparison of angiotensin-converting enzyme inhibitors in treatment of congestive heart failure. Am J Cardiol 2005, 95:283-286.
29. Trewet C.B., Shireman T.I., Rigler S.K., Howard P.A. Do ACE inhibitors/angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. Drugs Aging 2007, 24:945-955.
30. Shah B.R., Laupacis A., Hux J.E., Austin P.C. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005, 58:550-559.
31. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
32. Imbens G.W. The role of the propensity score in estimating dose-response functions. Biometrika 2000, 87:706-710.
33. Lechner M. Identification and estimation of causal effects of multiple treatments under the conditional independence assumption. Econometric Evaluation of Labour Market Policies 2001, 43-58. Heidelberg, Physica, Springer. M. Lechner, F. Pfeiffer (Eds.).
34. Joffe M., Rosenbaum P. Invited commentary: propensity scores. Am J Epidemiol 1999, 150:327-333.
35. Lu B., Zanutto E., Hornik R., Rosenbaum P. Matching with doses in an observational study of a media campaign against drug abuse. J Am Stat Assoc 2001, 96:1245-1253.
36. Spreeuwenberg M.D., Bartak A., Croon M.A., et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care 2010, 48:166-174.
37. McCullough P.A., Philbin E.F., Spertus J.A., Kaatz S., Sandberg K.R., Weaver W.D. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002, 39:60-69. Resource Utilization Among Congestive Heart Failure (REACH) Study.
38. Karve S., Cleves M.A., Helm M., et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009, 25:2303-2310.
39. Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15:565-574.
40. Deswal A., Petersen N.J., Souchek J., Ashton C.M., Wray N.P. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J Am Coll Cardiol 2004, 43:778-784.
41. Leslie S, Thiebaud P. Using propensity scores to adjust for treatment selection bias. SAS global forum, statistics and analysis. Paper 184-2007. Available at: Accessed 11.04.09. http://www2.sas.com/proceedings/forum2007/184-2007.pdf.
42. Hirano K., Imbens G. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcom Res Methodol 2001, 2:259-278.
43. McNiel D.E., Binder R.L. Effectiveness of a mental health court in reducing criminal recidivism and violence. Am J Psychiatry 2007, 164:1395-1403.
44. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-461.
45. Mortensen E.M., Restrepo M.I., Copeland L.A., Pugh J.A., Anzueto A. Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality. Am J Med Sci 2008, 336:462-466.
46. Moskowitz D.W., Johnson F.E. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem 2004, 4:1433-1454.
47. Wei L., Clauser E., Alhenc-Gelas F., Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992, 267:13398-13405.
48. Ondetti M.A. Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation 1988, 77(6 Pt 2):I74-178.
49. Bertrand M.E. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004, 20:1559-1569.
50. Johnson M.L., Bush R.L., Collins T.C., et al. Propensity score analysis in observational studies: outcomes after abdominal aortic aneurysm repair. Am J Surg 2006, 192:336-343.
51. Ashton C.M., Petersen N.J., Souchek J., et al. Geographic variations in utilization rates in Veterans Affairs hospitals and clinics. N Engl J Med 1999, 340:32-39.
52. Hogg K., Swedberg K., Mcmurray J. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004, 43:317-327.
53. Lau H.S., de beer A., Beuning K.S., Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997, 50:619-625.
54. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100:2312-2318.